News

NEW YORK and WALTHAM, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of ...
TARRYTOWN, N.Y., April 29, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the first quarter of 2025 and provided a business update.
Sheding Weight, not only helps you shed weight, but Mitolyn is unique as it naturally and totally enhances your health, ...
When blood sugar spikes and crashes, it can cause feelings of fatigue, irritability, and mood swings. Keeping blood sugar ...
Increase in semen volume: after consuming a single dosage of Volume Pills, men might begin to experience enhanced sexual ...
deepull secures oversubscribed €50 million Series C financing to advance UllCORE diagnostic system for direct-from-blood rapid pathogen detection Round co-led by Columbus Venture Partners, Panakès ...
The financing will enable Nova Anchora to advance its lead candidate NvA-011, a recombinant collagen therapy, through IND-enabling studies. The investment underscores the backers’ commitment to ...
In addition, a further 1,220,000 options have been granted under a non-tax advantaged option scheme. These options also have a vesting period of 2 years with one third vesting on grant, one third on ...
Basel, 29 April 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation for the VENTANA® TROP2 (EPR20043) ...
The Board of Directors of Financière de Tubize appoints Bruno Holthof as new Chair ...
Allschwil, Switzerland – April 29, 2025 Idorsia Ltd (SIX: IDIA) today announced the publication of “ Effect of daridorexant on nighttime wakefulness and next-morning sleepiness: assessing the ...
FDA granted an accelerated approval for Vanrafia for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression. Vanrafia can be ...